Xintela granted 4.8 million SEK from Vinnova

Xintela granted 4.8 million SEK from Vinnova

Xintela has been granted SEK 4.8 million from Vinnova within the call "New and improved biological drugs in healthcare". The grant will support a clinical phase I/IIa study to evaluate Xintela's stem cell product XSTEM® for the treatment of patients with difficult-to-heal leg ulcers.

The project, which will be partly financed by Vinnova, aims to evaluate the safety and efficacy of Xintela's stem cell product XSTEM in a clinical phase I/IIa study for treatment of difficult-to-heal venous leg ulcers, a painful disease that affects about 4% of the population over 65 years. The clinical study will be performed in collaboration with Professor Folke Sjöberg and his team at the Burn Center at Linköping University Hospital.

Xintela's application received the maximum grant, where 9 applications were granted a total of SEK 45 million in funding.

-It is very gratifying that Vinnova has approved our application, which shows that our project is of high quality and competitive. The medical need in patients with difficult-to-heal venous leg ulcers is huge and entails significant costs for healthcare. The financial support from Vinnova helps us to develop XSTEM into a new and effective treatment for this large patient group, says Xintela's CEO Evy Lundgren-Åkerlund.


Xintela AB